

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
23 January 2003 (23.01.2003)

PCT

(10) International Publication Number  
WO 03/006988 A1

(51) International Patent Classification<sup>7</sup>: G01N 33/50,  
C07D 401/12, C07M 5/00, G01N 33/68, 33/60

(21) International Application Number: PCT/EP02/07364

(22) International Filing Date: 2 July 2002 (02.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
01202689.4 13 July 2001 (13.07.2001) EP

(71) Applicant (for all designated States except US):  
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HEYLEN, Godelieve, Irma, Christine, Maria [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). JANSSEN, Cornelus, Gerardus, Maria [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). JURZAK, Mirek [DE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). VAN ASSOEW, Henricus, Petrus, Martinus, Maria [NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: JANSSEN PHARMACEUTICA N.V.; Patent Department, Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

— of inventorship (Rule 4.17(iv)) for US only

**Published:**

— with international search report

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CARDIOVASCULAR SAFETY ASSAY

(57) Abstract: The present invention provides assays and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. Said assays and kits are based on the finding that the interaction of astemizole with the HERG potassium channel can be exploited to predict cardiotoxicity of compounds during the development of new therapeutics and other agents.

Best Available Copy

WO 03/006988 A1

## CARDIOVASCULAR SAFETY ASSAY

The present invention relates to the field of cardiovascular safety assays and provides assays and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. Said assays and kits are based on the finding that the interaction of astemizole with the HERG potassium channel can be exploited to predict potential cardiotoxicity of compounds during the development of new therapeutics and other agents. The present invention finds particularly advantageous use in high throughput screening of chemical compound libraries.

### BACKGROUND OF THE INVENTION

Evidence has accrued that several drugs may prolong cardiac repolarisation (hence, "measured as" the QT interval of the surface electrocardiogram) to such a degree that potentially life-threatening ventricular arrhythmias *e.g.* torsades de pointes (TdP) may occur, especially in case of overdosage or pharmacokinetic interaction.

The number of drugs reported to induce QT interval prolongation, with or without TdP continues to increase (W. Haverkamp *et al.* (2000) Cardiovascular Research 47, 219-233). As many as 50 clinically available or still investigational non-cardiovascular drugs and cardiovascular non-anti-arrhythmic drugs have been implicated. A number of drugs, both old and new, have either been withdrawn from the market or have had their sale restricted. Of concern is the interval, usually measured in years, from the marketing of these drugs to initial recognition of their association with QT interval prolongation and / or TdP. It would therefore be beneficial to investigate any new chemical entity for this potential side effect before its first use in man at an early stage of the development of new therapeutics and / or other agents.

A key component in the present development of new therapeutic agents consists of High Throughput Screening (HTS) of chemical compound libraries. Pharmaceutical companies have established large collections of structurally distinct compounds, which act as the starting point for drug target lead identification programs. A typical corporate

compound collection now comprises between 100,000 and 1,000,000 discrete chemical entities. While a few years ago a throughput of a few thousand compounds a day and per assay was considered to be sufficient, pharmaceutical companies nowadays aim at ultra high throughput screening techniques with several hundreds of thousands of compounds tested per week. In a typical HTS related screen format, assays are performed in multi-well microplates, such as 96, 384 or 1536 well plates. The use of these plates facilitates automation such as the use of automated reagent dispensers and robotic pipetting instrumentation. Further, to reduce the cycle time, the costs and the resources for biochemicals such as recombinant proteins, HTS related screens are preferably performed at room temperature with a single measurement for each of the compounds tested in the assay.

A decisive criterion in the lead evaluation process will be an early recognition of their potential association with QT prolongation and / or TdP. However, there are currently no reliable, fast, easy screening methods available to assess cardiotoxicity, which can cope with the number of compounds identified in the currently deployed HTS techniques. It is an object of this invention to solve this problem in the art by providing assays and kits which are based on the finding that the interaction of astemizole with the HERG potassium channel can be exploited to predict cardiotoxicity of compounds during the development of new therapeutics and other agents.

The currently available *in vitro* models comprise heterologous expression systems, disaggregated cells, isolated tissues and the isolated intact (Langendorff-perfused) heart. In all models the effect of potassium current blockade is assessed by measurement of either ionic currents using two-electrode voltage clamp recordings (Dascal N. (1987) Crit.Rev.Biochem 22, 341-356) or patch-clamp recordings (Zhou Z. *et al.*, (1998) Biophysical Journal 74, 230-241), of membrane potentials using microelectrodes or confocal microscopy (Dall'Asta V. *et al.* (1997) Exp.Cell Research 231, 260-268). None of the aforementioned methods can be used in an HTS screen in view of the complexity of the experimental procedures, the slow cycling times, the nature of the source materials (i.e. isolated tissues and disaggregated cells thereof) and the reliability of the test results.

The present inventors surprisingly found that a binding assay using labeled

astemizole as a specific ligand for the HERG channel can be used to predict the potential association of compounds with QT prolongation and / or TdP. This binding assay solves the aforementioned problems and can be deployed in an HTS related screen format.

5 A similar assay has been described by Chadwick C. *et al.* (Chadwick C. *et al.*, (1993) *Circulation Research* 72, 707-714) wherein [ $^3\text{H}$ ]-dofetilide has been identified as a specific radioligand for the cardiac delayed rectifier  $\text{K}^+$ -channel. This article further demonstrates a good correlation between dofetilide displacement and potassium channel blocking activity of a number of antiarrhythmic compounds.  
10 This binding assay facilitates the characterization of drug-channel interactions at the molecular level.

In this assay labeled dofetilide has been prepared from the dibromo precursor by  $^3\text{H}$ -exchange yielding the incorporation of two  $^3\text{H}$ -labels per molecule. There is a direct correlation between the number of  $^3\text{H}$ -labels per molecule and the  
15 sensitivity of the binding assay. The present invention provides an improved binding assay over the above, as the use of a desmethylastemizole precursor in a reaction with [ $^3\text{H}$ ]-methyl iodide resulted in the incorporation of three  $^3\text{H}$ -labels per molecule astemizole. The specific activity of the thus obtained radioligand is 1.5 – 2 times higher than the specific activity of [ $^3\text{H}$ ]-dofetilide.

20 Further, the dofetilide assay could not be used in an HTS related screen format since the ventricular myocytes isolated from adult male guinea pigs had to be used within 6 hours of isolation. In addition only 36% of the isolated cells were viable and could be used in the binding assay. In order to be used in an HTS related screen, the starting material should be readily available and in sufficient amounts.  
25 The present invention solves this problem as membrane preparations of HEK293 cells, stably expressing the HERG potassium channel, are used. Said cells can be maintained in culture in sufficient amount avoiding the need and supply of animal models and as cell membranes are used in the binding assay, the latter can be stored in binding assay ready aliquots at  $-80^\circ\text{C}$  for later use. A further drawback of the  
30 dofetilide binding assay described by Chadwick *et al.* has to do with the incubation protocol. As viable myocytes are used, the incubation has to be performed at the

physiological temperature of 34°C. The latter undoubtedly increases the costs, possible cycle time and complexity of the assay if to be performed in an HTS related screen format. The present invention solves this problem as it was surprisingly demonstrated that the membrane preparations could be incubated at room temperature. Especially in light of a study by Zhou Z. *et al.* Zhou Z. *et al.*, (1998) Biophysical Journal 74, 230-241) which concluded that the kinetic properties measured for HERG are markedly dependent on temperature and that differences observed in several reports, are diminished when studies are performed at physiological temperatures, i.e. 35 °C.

This and other aspects of the invention will be described herein below.

#### SUMMARY OF THE INVENTION

The present invention provides an assay for screening test compounds for their capability to induce cardiotoxicity in a subject, the method comprising incubating a source containing HERG or a fragment thereof with a reference compound and the test compound, for a time sufficient to allow binding of the reference compound and of the test compound with the HERG polypeptide channel and measuring the effect of the test compound on the amount of reference compound bound to HERG.

In a preferred embodiment of this invention, the assay consists of incubating membrane preparations of cells, preferably HEK293 cells, expressing on the surface thereof the HERG polypeptide channel comprising the amino acid sequence of SEQ ID NO:2 or a fragment thereof; with a labeled reference compound. Wherein said labeled reference compound is a drug capable to induce cardiac arrhythmia in a subject, preferably said labeled reference compound is [<sup>3</sup>H]-astemizole. Incubating the above together with the test compound and measure the effect of the test compound on the amount of reference compound bound to the HERG polypeptide channel. In a further embodiment the means of measurement consist of separating means to remove the excess of unbound labeled reference compound from the incubation mixture and of means for detection of the labeled reference compound

wherein the latter preferably consists of radiolabeled measurement using scintillation counting.

The invention further provides a high-throughput assay for screening compounds for their capability to induce cardiotoxicity in a subject, the assay

5 comprising;

a) contacting membrane preparations of cells expressing on the surface thereof HERG polypeptide channels having an amino acid sequence that is at least 80% identical to that of SEQ ID NO:2 or fragments thereof, with a labeled reference compound for a time sufficient to allow binding of the reference compound with the HERG polypeptide channel;

10

b) contacting membrane preparations of cells expressing on the surface thereof HERG polypeptide channels having an amino acid sequence that is at least 80% identical to that of SEQ ID NO:2 or fragments thereof, with the labeled reference compound of step a) together with the test compound for a time sufficient to allow binding of the reference compound and of the test compound with the HERG polypeptide channel;

15

c) measuring the amount of labeled reference compound bound to the HERG channel in step a);

d) measuring the amount of labeled reference compound bound to the HERG channel in step b); and

20

e) compare the amount of labeled reference compound bound to the HERG channel measured in step a) with the amount of labeled reference compound bound to the HERG polypeptide channel measured in step b).

In a preferred embodiment of the high-throughput screening assay, the membrane preparations are derived from cells, preferably HEK293 cells, expressing on the surface thereof HERG polypeptide channels encoded by the amino acid sequence consisting of SEQ ID NO:2. In a further embodiment of the high-throughput screening assay the labeled reference compound is astemizole, preferably [<sup>3</sup>H]-astemizole.

25

The present invention also encompasses kits for screening compounds for their capability to induce cardiotoxicity in a subject as well as the use of reagents, including polynucleotides, polypeptides and suitable reference compounds in the assays of the present invention.

5

#### BRIEF DESCRIPTION OF THE DRAWING

Figure 1 A shows the saturation binding of [<sup>3</sup>H]-astemizole to cell membrane preparations of HEK293 cells stably transfected with the HERG channel cDNA. TB represents Total Binding measured, NSB represents Non Specific Binding measured and SB represents Specific Binding measured.

10

Figure 1B shows the Scatchard plot for the saturation binding experiments. From the fitted line a  $K_D$  of  $3.07 \pm 2.26$  nM ( $n=11$ ) could be determined with a  $B_{max}$  (Maximal Binding) of  $3260 \pm 900$  fmol/mg protein ( $n=11$ ).

Figure 2 shows the binding affinities of 42 reference compounds compared to the electrophysiological patch clamp data. A Spearman rank correlation coefficient of 0.87 could be obtained.

15

#### DETAILED DESCRIPTION

The present invention relates to the field of cardiovascular safety assays and provides assays and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. Said assays and kits are based on the finding that the interaction of astemizole with the HERG potassium channel can be exploited to predict cardiotoxicity of compounds during the development of new therapeutics and other agents. The present invention finds particularly advantageous use in high throughput screening of chemical compound libraries.

20

In one embodiment of the present invention, the assay for screening test compounds comprises: a) incubating a source containing HERG or a fragment thereof with i) a reference compound, ii) the test compound; and b) measuring the effect of the test compound on the amount of reference compound bound to HERG.

25

In a specific embodiment of the present invention the assays are used to assess the capability of the test compounds to induce cardiac arrhythmia in a subject.

30

As used herein the term "test compound" refers to a chemically defined molecule whose cardiac arrhythmia inducing capability is assessed in an assay according to the invention. Test compounds include, but are not limited to, drugs, ligands (natural or synthetic), polypeptides, peptides, peptide mimics, polysaccharides, saccharides, glycoproteins, nucleic acids, polynucleotides and small organic molecules. In one embodiment test compounds comprise an existing library of compounds. In another embodiment, test compounds comprise a novel library of compounds.

As used herein the term "reference compound" refers to a drug capable to induce cardiotoxicity in a subject. Reference compounds include, but are not limited to, astemizole, terfenadine, erythromycin, sparfloxacin, probucol, terodiline and sertindole.

As used herein the term "HERG" refers to the Human Ether-a-go-go-Related Gene channel. It is a delayed rectifier potassium channel that plays a role in the control of action potential repolarization in many cell types. HERG was originally cloned from human hippocampus and it is strongly expressed in the heart. The HERG polypeptides according to the invention include isolated and purified proteins having an amino acid sequence that is at least 80% identical to that of SEQ ID NO:2 or a fragment thereof. In a further embodiment the HERG polypeptide channel according to the invention has an amino acid sequence comprising the amino acid sequence of SEQ ID NO:2. In a preferred embodiment the HERG polypeptide according to the invention consists of SEQ ID NO:2.

Variants of the defined sequence and fragments also form part of the invention. Variants include those that vary from the parent sequence by conservative amino acid changes, wherein "conservative amino acid changes" refers to the replacement of one or more amino acid residue(s) in the parent sequence without affecting the biological activity of the parent molecule based on the art recognized substitutability of certain amino acids. (See e.g. M. Dayhoff, In Atlas of Protein Sequence and Structure, Vol.5, Supp. 3, pgs 345-352, 1987). Further variants are variants in which several, 5-10, 1-5, or 1-2 amino acids are substituted, deleted or added in any combination.



Methods for comparing the identity and similarity of two or more sequences are well known in the art. Thus for instance, programs available in the Winconsin Sequence Analysis Package, version 9.1 (Devreux J. *et al*, Nucleic Acid Res., 12, 387-395, 1984), for example the programs BESTFIT and GAP, may be used to  
5 determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (J. Mol. Biol., 147, 195-197, 1981) and finds the best single region of similarity between two sequences. BESTFIT is more suited to compare two polynucleotide or two polypeptide sequences that are  
10 dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP aligns two sequences, finding a "maximum similarity", according to the algorithm of Neddleman and Wunsch (J.Mol.Biol., 48, 443-453, 1970). GAP is more suited to compare sequences that are approximately the same length and an alignment is expected over the entire  
15 length. Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3 for polynucleotide sequences, and 12 and 4 for polypeptide sequences, respectively. Preferably, % identities and similarities are determined when the two sequences being compared are optimally aligned. Other programs for determining identity and/or similarity between sequences are also known in the art,  
20 for instance the BLAST family of programs (Altschul S F *et al*, Nucleic Acids Res., 25:3389-3402, 1997).

Those skilled in the art will recognize that the polypeptides according to the invention, i.e. the HERG polypeptide channel, could be obtained by a plurality of recombinant DNA techniques including, for example, hybridization, polymerase  
25 chain reaction (PCR) amplification, or *de novo* DNA synthesis (See e.g., T. Maniatis *et al*. Molecular Cloning: A Laboratory Manual, 2d Ed. Chap.14 (1989)). Thus, in a further embodiment the present invention provides the use of the isolated and purified polynucleotides encoding the HERG polypeptide or a fragment thereof, in an assay or kit according to the invention. In another embodiment the present  
30 invention provides the use of the isolated and purified polynucleotide encoding the HERG polypeptide channel or a fragment thereof comprising the polynucleotide

sequence of SEQ ID NO:1. In a preferred embodiment the present invention provides the use of the isolated and purified polynucleotide encoding the HERG polypeptide channel consisting of the polynucleotide sequence of SEQ ID NO:1.

The term "fragments thereof" describes a piece, or sub-region of protein or polynucleotide molecule whose sequence is disclosed herein, such that said  
5 fragment comprises 5 or more amino acids that are contiguous in the parent protein, or such that said fragment comprises 15 or more nucleic acids that are contiguous in the parent polynucleotide. The term "fragments thereof" is intended to include "functional fragments" wherein the isolated fragment, piece or sub-region  
10 comprises a functionally distinct region such as an active site, a binding site or a phosphorylation site of the receptor protein. Functional fragments may be produced by cloning technology, or as the natural products of alternative splicing techniques.

As used herein, "isolated" refers to the fact that the polynucleotides, proteins and polypeptides, or respective fragments thereof in question, have been removed  
15 from its *in vivo* environment so that it can be manipulated by the skilled artisan, such as but not limited to sequencing, restriction digestion, site-directed mutagenesis, and subcloning into expression vectors for a nucleic acid fragment as well as obtaining the protein or protein fragments in quantities that afford the opportunity to generate polyclonal antibodies, monoclonal antibodies, amino acid  
20 sequencing, and peptide digestion.. Therefore, the nucleic acids as described herein can be present in whole cells or in cell lysates or in a partially, substantially or wholly purified form.

A polypeptide is considered "purified" when it is purified away from environmental contaminants. Thus a polypeptide isolated from cells is considered  
25 to be substantially purified when purified from cellular components by standard methods while a chemically synthesized polypeptide sequence is considered to be substantially purified when purified from its chemical precursors. A "substantially pure" protein or nucleic acid will typically comprise at least 85% of a sample with greater percentages being preferred. One method for determining the purity of a  
30 protein or nucleic acid molecule, is by electrophoresing a preparation in a matrix such as polyacrylamide or agarose. Purity is evidenced by the appearance of a

single band after staining. Other methods for assessing purity include chromatography and analytical centrifugation.

The term "time sufficient to allow binding" as used herein refers to the time needed to generate a detectable amount of labeled reference compound bound to the

5 HERG polypeptide channel. The time needed to generate this detectable amount will vary depending on the assay system. One of skill in the art will know the amount of time sufficient to generate a detectable amount of labeled reference compound bound to the HERG polypeptide channel based upon the assay system.

## 10 Assays

Assays of the present invention can be designed in many formats generally known in the art of screening compounds for binding polypeptide channels.

The assays of the present invention advantageously exploit the fact that the interaction of astemizole with the HERG potassium channel can be exploited to

15 predict cardiotoxicity of compounds during the development of new therapeutics and other agents.

Therefore, the present invention provides an assay for screening test compounds, the assay comprising a) incubating a source containing HERG or a fragment thereof with; i)

20 a reference compound, ii) the test compound; and b) measuring the effect of the test compound on the amount of reference compound bound to HERG.

In a first embodiment of this invention the source containing HERG is an isolated and purified protein which encodes HERG having an amino acid sequence

25 that is at least 80% identical to that of SEQ ID NO:2 or a fragment thereof.

In a second embodiment of this invention the source containing HERG is an isolated and purified protein which encodes HERG comprising the amino acid sequence of SEQ ID NO: 2 or a fragment thereof.

In a further embodiment of this invention the source containing HERG are

30 cells expressing on the surface thereof the HERG polypeptide channel or a fragment thereof.

In another embodiment of this invention the source containing HERG are membrane preparations of cells expressing on the surface thereof the HERG polypeptide channel or a fragment thereof.

5 In an alternative embodiment of this invention, the reference compound is a compound capable to induce cardiotoxicity in a subject, preferably selected from the group consisting of astemizole, terfenadine, erythromycin, sparfloxain, probucol, terodiline and sertindole. In a preferred embodiment the reference compound is astemizole. It is a further object of this invention to provide assays wherein the reference compound is labeled, preferably radiolabeled.

10 In a preferred embodiment, the assay for screening test compounds for their capability to induce cardiotoxicity in a subject consists of a) incubating membrane preparations of cells expressing on the surface thereof HERG polypeptide channels encoded by the amino acid sequence consisting of SEQ ID NO:2 with i) [<sup>3</sup>H]-astemizole, ii) the compound to be tested; and measuring the effect of the test  
15 compound on the amount of reference compound bound to HERG. The label of the reference compound is used to measure this effect wherein said label can be measured using amongst others scintillation counting.

A specific embodiment of the assays according to the invention, consists of an high-throughput assay for screening test compounds, the assay comprising: a)  
20 contacting membrane preparations of cells expressing on the surface thereof HERG polypeptide channels having an amino acid sequence that is at least 80% identical to that of SEQ ID NO:2 or fragments thereof, with a labeled reference compound for a time sufficient to allow binding of the reference compound with the HERG polypeptide channel; b) contacting membrane preparations of cells expressing on the surface thereof  
25 HERG polypeptide channels having an amino acid sequence that is at least 80% identical to that of SEQ ID NO:2 or fragments thereof, with the labeled reference compound of step a) together with the test compound for a time sufficient to allow binding of the reference compound and of the test compound with the HERG polypeptide channel; c) measuring the amount of labeled reference compound bound to  
30 the HERG channel in step a); d) measuring the amount of labeled reference compound bound to the HERG channel in step b); and e) compare the amount of labeled reference

compound bound to the HERG channel measured in step a) with the amount of labeled reference compound bound to the HERG polypeptide channel measured in step b).

In a further embodiment the membrane preparations of the high-throughput screening assay consist of membrane preparations of cells expressing on the surface thereof the HERG polypeptide channel comprising the amino acid sequence of SEQ ID NO:2 or fragments thereof.

In a preferred embodiment of this invention the membrane preparations of the high-throughput screening assay consist of membrane preparations of cells, preferably HEK 293 cells, expressing on the surface thereof HERG polypeptide channels consisting of the amino acid sequence of SEQ ID NO:2.

In a further preferred embodiment, the labeled reference compound in the high-throughput screening assay consists of [<sup>3</sup>H]-labeled astemizole. Said label can be measured using amongst others scintillation counting.

In another specific embodiment the present invention provides a high-throughput proximity detection assay for screening test compounds the assay comprising:

- i) HERG labeled with a first label capable of participating in a proximity detection assay;
- ii) a reference compound labeled with a second label capable of participating in a proximity detection assay;
- iii) contacting HERG of step i) and a reference compound of step ii) together with a test compound for a time sufficient to allow binding of the reference compound and of the test compound to HERG; and
- iv) detect an interaction between HERG of step i) and a reference compound of step ii) by means of proximity of the first label with the second label when HERG and the reference compound interact.


The proximity of the first label to the second label, brought about by the interaction of HERG and the reference compound results in the production of a detectable signal. This may be achieved by e.g. a scintillation proximity assay (SPA) system, in which one of the labels is a radiolabel suitable for use in SPA and the other label is a fluorescer comprised in a solid phase. The detectable signal is light energy emitted when the labeled HERG protein interacts with the labeled reference compound,

bringing the radiolabel sufficiently close to the fluorescer. Scintillation proximity assay technology is described in US 4,568,649.

Alternatively, the detectable signal may be a change in an existing signal output, eg. fluorescence. Fluorescence resonance energy transfer (FRET) is a method which works on this principle and is described by Tsien R. *et al.* (Tsien R. *et al.* (1993) Trends Cell Biol. 3: 242-245). It employs two different fluorescent molecules, a donor and an acceptor, such that when these are in sufficient proximity to one another the fluorescence of the donor molecule is absorbed by the acceptor molecule and light of another wavelength is emitted. Thus, when there is an interaction between two molecules such as HERG and a reference compound, each of which is labeled with one of these fluorescent molecules, a detectable signal is produced.

By such proximity assays as are described above, the screening assay according to the invention may be performed in a single step, i.e. without the need of a separation step to remove the excess of labeled reference compound from the incubation mixture using separation means such as filtration.

In a preferred embodiment of the high-throughput proximity detection assay, HERG is labeled with the fluorescer comprised in a solid phase, such as coated scintillation proximity assay beads and the reference compound is labeled with the radiolabel preferably the reference compound is radiolabeled astemizole of formula (III).



III

It will be readily appreciated by the skilled artisan that the binding of astemizole with HERG may also be used in a method for the structure-based or rational design of compound which affects the aforementioned binding, by:

- probing the structure of the binding site of the HERG polypeptide channel with astemizole;

- b) identifying contacting atoms in the binding site of the HERG polypeptide channel that interact with astemizole during binding;
- c) design test compounds that interact with the atoms identified in (b) to affect the HERG – astemizole interaction; and
- 5 d) contact said designed test compound with a source containing HERG or a fragment thereof, to measure the capability of said compound to affect the amount of labeled astemizole bound to HERG.

It will be further appreciated that this will normally be an iterative process.

#### 10 Kits

The present invention also provides kits that can be used in the above assays. In one embodiment the kit comprises a) a source containing HERG; b) a reference compound.

- 15 In a first embodiment the kit comprises a source containing HERG selected from: i) an isolated and purified protein which encodes HERG having an amino acid sequence that is at least 80% identical to that of SEQ ID NO:2 or a fragment thereof; ii) an isolated and purified protein which encodes HERG comprising the amino acid sequence of SEQ ID NO:2 or a fragment thereof; iii) cells expressing on the surface thereof the HERG polypeptide channel or a fragment thereof; or iv) membrane
- 20 preparations of cells expressing on the surface thereof the HERG polypeptide channel or a fragment thereof.

- In a further embodiment the kit comprises a reference compound is selected from the group consisting of astemizole, terfenadine, erythromycin, sparfloxain, probucol, terodiline and sertindole. In a preferred embodiment the reference compound
- 25 is astemizole. It is a further object of this invention to provide kits wherein the reference compound is labeled, preferably radiolabeled.

In a specific embodiment the isolated and purified HERG polypeptide channel is bound to a solid support, preferably to a fluorescer comprising solid support such as coated scintillation proximity beads.

- 30 Thus, in a specific embodiment the kit comprises a) an isolated and purified HERG polypeptide channel or a fragment thereof, bound to a solid support; and b) a

labeled reference compound. Preferably this specific embodiment consists of a kit comprising a) an isolated and purified HERG polypeptide channel consisting of the amino acid sequence of SEQ ID NO:2, bound to fluorescer comprising solid support; and b) a radiolabeled reference compound, preferably [<sup>3</sup>H]-labeled astemizole.

5 In another specific embodiment the kit comprises a) membrane preparations of cells, preferably HEK293 cells, expressing on the surface thereof the HERG polypeptide channel consisting of the amino acid sequence of SEQ ID NO:2; b) [<sup>3</sup>H]-labeled astemizole; and c) means for measurement of the amount of labeled reference compound bound to HERG.

10 The means of measurement consist of separating means to remove the excess of unbound labeled reference compound from the incubation mixture and of means for detection of the labeled reference compound. The person skilled in the art will know the separating means available for removing the excess of unbound labeled reference compound from the incubation mixture. Said separating means include, but are not  
15 limited to, magnetic beads, centrifugation techniques and filtration techniques. The means for detecting the labeled reference compound will be dependend on the labeled used. Said labels may be fluorescent or radiolabels. The skilled man will know the detection means available depending on the label used.

In a specific embodiment the separating means consists of GF/B filtration  
20 (Whatman Inc, Clifton, N.J.). In another specific embodiment the detection means consists of scintillation counting in a Topcount (Packard, Meriden, CT).

In a further embodiment the kits of the invention further comprise instructions and/or multiple well plates for performing the assay.

This invention will be better understood by reference to the Experimental Details  
25 that follow, but those skilled in the art will readily appreciate that these are only illustrative of the invention as described more fully in the claims that follow thereafter. Additionally, throughout this application, various publications are cited. The disclosure of these publications is hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains.




EXAMPLE 1: DNA constructs and stable transfection of HEK293 cells

HERG cDNA (Genbank Accession number: U04270 (SEQ ID NO:1)) was subcloned into *bamHI/EcoRI* sites of the pcDNA3 vector (Invitrogen). This vector contains a CMV promoter and a SV40 promoter, which drive the expression of the inserted cDNA (HERG) and neomycin resistance gene, respectively. The HEK293 cells were transfected with this construct by a calcium phosphate precipitate method (Gibco) or a lipofectamine method (Gibco). After selection in 800  $\mu\text{g/ml}$  geneticin (G418; Gibco) for 15-20 days, single colonies were picked with cloning cylinders and tested for HERG current. The stably transfected cells were cultured in minimum essential medium (MEM) supplemented with 10% fetal bovine serum and 400  $\mu\text{g/ml}$  geneticin.

For electrophysiological study, the cells were harvested from the culture dish by trypsinization, washed twice with standard MEM medium and seeded on small petri-dishes coated with poly-L-lysine. Experiments were performed on the cells 1-2 days after plating.

EXAMPLE 2: Membrane preparations of HEK293 cells stably transfected with the HERG potassium channel

HEK293 cells stably transfected with the HERG channel cDNA, were grown in DMEM culture medium enriched with 10 % fetal calf serum and antibiotics. Collected cells were homogenized in Tris-HCl 50 mM pH 7.4 using an Ultraturrax homogenizer and the homogenate was centrifuged for 10 min at 23,500 x g in a Sorvall centrifuge. The cell membranes were washed once by re-homogenization and re-centrifugation. The membranes were suspended in Tris-HCl 50 mM pH 7.4, aliquoted and stored at -80 C.


EXAMPLE 3: Radiolabeling of astemizole

5 A solution of 4.6g of astemizole (I) (10 mmol) in a 48% aqueous hydrobromic acid solution (80 ml) was stirred and refluxed for 2 hours. The reaction mixture was allowed to cool to room temperature and the formed precipitate was filtered and washed with water. The solids were dissolved in a mixture of *N,N*-dimethylformamide (20 ml) and water (20 ml) and the mixture was made alkaline by introducing slowly and with stirring a concentrated aqueous ammoniumhydroxide solution. Then water (100 ml)

10 was added and the mixture was stirred for 1h. The precipitate was filtered off and dried to the air for 18h to yield desmethylastemizole (II).

From this amount a fraction was taken and thoroughly purified in portions via preparative HPLC on a Hypersyl ODS (5  $\mu$ m) bonded phase stainless steel column (7.1

15 mm ID x 300 mm) to yield astemizole free desmethylastemizole. Detection took place at 282 nm and elution was performed isocratically with acetonitrile-water-diisopropylamine (56:44:0.2,v/v) at a flow rate of 4.0 ml/min.



A fraction of the HPLC purified desmethylastemizole (II) (26.7 mg, 60  $\mu$ mol) was dissolved in *N,N*-dimethylformamide (1.0 ml). To this solution 1N aqueous sodium hydroxide solution (60  $\mu$ l, 60  $\mu$ mol) was added. The mixture was stirred for 25 minutes at room temperature and added dropwise to a precooled solution ( $-78^{\circ}\text{C}$ ) of [ $^3\text{H}$ ]-methyl iodide (370 MBq) in toluene. The reaction mixture was vortexed and then left without cooling for 3 hours. The toluene was evaporated from the reaction mixture on a waterbath of  $40^{\circ}\text{C}$  at aspirator pressure and the residue was purified in portions via preparative HPLC as described above. The product containing fractions were combined and depleted to 70 ml with methanol to give [ $^3\text{H}$ ]-astemizole (III) with a total radioactivity of 198 MBq and a specific activity of 3.14 TBq/mmol (85 Ci/mmol).

#### EXAMPLE 4: Radioligand Binding Assay

Membranes were thawed and re-homogenized in incubation buffer (Hepes 10 mM pH 7.4, 40 mM KCl, 20 mM  $\text{KH}_2\text{PO}_4$ , 5 mM  $\text{MgCl}_2$ , 0.5 mM  $\text{KHCO}_3$ , 10 mM glucose, 50 mM glutamate, 20 mM aspartate, 14 mM heptanoic acid, 1 mM EGTA, 0.1 % BSA) and 20-100  $\mu$ g protein was incubated with [ $^3\text{H}$ ]-astemizole for 60 min at  $25^{\circ}\text{C}$  with or without competitor followed by rapid filtration over GF/B filter using a Filtermate196 harvester (Packard, Meriden, CT). Filters were rinsed extensively with ice-cold rinse-buffer (Tris-HCl 25 mM pH 7.4, 130 mM NaCl, 5.5 mM KCl, 5 mM glucose, 0.8 mM  $\text{MgCl}_2$ , 50  $\mu$ M  $\text{CaCl}_2$ , 0.1 % BSA). Filter bound radioactivity was determined by scintillation counting in a Topcount (Packard, Meriden, CT) and results were expressed as counts per minute (cpm).

Initially, various parameters including buffer, radioligand and compound to determined non-specific binding, were investigated in order to select the optimal conditions.

5 In a saturation binding experiment, increasing concentrations of [<sup>3</sup>H]-astemizole were incubated with membranes, re-suspended in buffer. Non-specific binding was measured in the presence of 10  $\mu$ M R66204 (Fig1).

The effect of BSA and/or cyclodextrine present in the incubation buffer, and of various ways of compound addition prior to the experiment, was investigated by comparing the binding affinities of 22 reference compounds to the electrophysiology data. Compounds  
10 were dissolved in DMSO and further diluted in the same solvent using a MultiprobeII pipetting station (Packard, Meriden, CT). The final DMSO concentration in all experiments was 1 %. From this analysis it appears that compounds can be added directly from the DMSO stock solution. Attempts to increase the solubility of the compounds by addition of BSA and/or cyclodextrin did not improve the correlation  
15 significantly.

EXAMPLE 5: Whole-cell voltage clamp technique (patch clamp)

*Solutions:* The bath solution contained (in mM) 150 NaCl, 4 KCl, 5 glucose, 10 HEPES, 1.8 CaCl<sub>2</sub> and 1 MgCl<sub>2</sub> (pH 7.4 with NaOH). The pipette solution contained  
20 (in mM) 120 KCl, 5 EGTA, 10 HEPES, 4 MgATP, 0.5 CaCl<sub>2</sub> and 2 MgCl<sub>2</sub> (pH 7.2 with KOH). Compounds were dissolved in DMSO to obtain a stock solution of 10<sup>-2</sup> M or 10<sup>-1</sup> M. Control (= bath solution + DMSO) and test solutions (= bath solution + DMSO + compound to be tested) contained 0.3 %, 0.1 % or 0.03 % DMSO. Test and control solutions were applied to the cell under study using a Y-tube system, allowing  
25 to rapidly change solutions (less than 0.5 s) in the vicinity of the cell under study.

*Electrophysiological measurements:* A Petri dish containing attached HEK293 cells expressing HERG was fixed on the stage of a Patch Clamp Tower. An inverted microscope was used to observe the cells. The Petri dish was constantly perfused with  
30 the bath solution at room temperature.

Patch pipettes were pulled from borosilicate glass capillaries using a horizontal Flaming/Brown micropipette puller without further fire-polishing. The microelectrodes used had an input resistance between 1.5 and 3 M $\Omega$  when filled with the pipette solution.

- 5 The membrane current of the cells was measured at distinct membrane potentials with the patch clamp technique by means of an EPC-9 patch clamp amplifier. Data were acquired and analysed using the programs Pulse and Pulsefit (HEKA), DataAccess (Bruxton) and Igor (Wavemetrics). The current signals were low-pass filtered and subsequently digitised. The liquid junction potential was electronically corrected,  
10 before establishing the seal. After disruption of the membrane, the cell capacitance and the series resistance were compensated using the circuit of the EPC-9 patch clamp amplifier.

The holding potential was -80 mV. The HERG current (K<sup>+</sup>-selective outward current) was determined as the maximal tail current at -40 mV after a 2 second depolarization to  
15 +60 mV. Pulse cycling rate was 15 s. Before each test pulse a short pulse (0.5 s) from the holding potential to -60 mV was given to determine leak current. After establishing whole-cell configuration a 5 minute equilibration period allowed for internal perfusion of the cell with the pipette solution. Thereafter test pulses were given for 5 minutes to quantify the HERG current under control conditions. While continuing the pulse  
20 protocol, perfusion was switched from control solution to drug-containing solution. The effect of the drug was measured after 5 minutes of drug application. One to three concentrations of the drug were tested per cell (applied cumulatively).

*Parameter analysis of the measurements:* The HERG current was determined as the  
25 maximal tail current at -40 mV after a 2 second depolarization to +60 mV, starting from a holding potential of -80 mV.

During the initial 5 minutes measured in the presence of the control solution, the amplitude of the HERG-mediated membrane K<sup>+</sup> current gradually decreased with time (run-down). In order to quantify accurately the extent of block by the compounds, this  
30 continuous run-down of the K<sup>+</sup> current has to be taken into account. Therefore the time course of the K<sup>+</sup> current (measured at -40 mV) was fitted exponentially to the initial period of 5 minutes in control solution and extrapolated for the remainder of the

experiment. These extrapolations give the estimated amplitude of the current if no drug would have been given. To determine the extent of block by the compounds, the ratio of the measured current was calculated by dividing each measured current amplitude by the value of the fitted current at the same point in time.

5

**EXAMPLE 6: Pharmacological evaluation of the binding assay**

For the pharmacological evaluation of the binding assay, 322 compounds were tested at 8 concentrations, for their ability to inhibit [<sup>3</sup>H]-astemizole binding to the HERG channel and pIC<sub>50</sub>-values were calculated by non-linear regression analysis. If pIC<sub>50</sub> values were available, the rank order (Spearman) of the potencies for binding and patch clamp was compared.

10

If in the patch clamp assay, compounds only have been tested at < 4 concentrations, a score was assigned to both binding- and patch clamp data according to the following criteria:

15

score 1: pIC<sub>50</sub> < 6 or %blockade < 50% at 10<sup>-6</sup> M or higher

score 2: pIC<sub>50</sub> between 6-8 or %blockade < 50% between 10<sup>-6</sup> and 10<sup>-8</sup> M

score 3: pIC<sub>50</sub> > 8 or %blockade > 50% at 10<sup>-8</sup> M or lower

20

The rank order of potencies of 42 reference compounds to displace the [<sup>3</sup>H]-astemizole binding from the HERG channel, correlates well with the electrophysiological data for the functional blockade of the rapid activating delayed rectifier K<sup>+</sup> current (r<sub>SP</sub> = 0.87) (Fig2).

25

For 94% of the compounds tested, the binding data correlate with the patch clamp data. In 2% of the cases the binding assay scored higher than the patch clamp assay, for the remaining 4% it is the other way around, i.e. the patch clamp assay scores higher than the binding assay.

In view of this good correlation between binding data and electrophysiological data it may be concluded that the radioligand binding assay can be used as a primary screening tool for the prediction of potential cardiovascular side-effects.

## SEQUENCE LISTING

<110> Janssen Pharmaceutica NV  
 5 <120> Cardiovascular Safety Assay  
 <130> Cardiovascular Safety Assay  
 10 <140>  
 <141>  
 <160> 2  
 <170> PatentIn Ver. 2.1  
 15 <210> 1.  
 <211> 4070  
 <212> DNA  
 <213> Homo sapiens  
 20 <220>  
 <221> CDS.  
 <222> (184)..(3663)  
 25 <300>  
 <301> Warmke, J. W.  
 <302> Human putative potassium channel subunit (h-erg) mRNA,  
 complete cds.  
 <308> GenBank / U04270  
 30 <309> 1993-12-09  
 <313> 1 TO 4070  
 <400> 1  
 35 acgcggcctg ctcaggcctc cagcggccgg tcggagggga ggcgggaggc gagcgaggac 60  
 ccgcgcccgc agtcagctc gtgcgcgcc gtgctcgtt ggcgcggtgc gggaccagcg 120  
 ccggccaccc gaagcctagt gcgtcgccgg gtgggtgggc ccgccggcg ccatgggctc 180  
 40 agg atg ccg gtg cgg agg ggc cac gtc gcg ccg cag aac acc ttc ctg 228  
 Met Pro Val Arg Arg Gly His Val Ala Pro Gln Asn Thr Phe Leu  
 1 5 10 15  
 45 gac acc atc atc cgc aag ttt gag ggc cag agc cgt aag ttc atc atc 276  
 Asp Thr Ile Ile Arg Lys Phe Glu Gly Gln Ser Arg Lys Phe Ile Ile  
 20 25 30  
 gcc aac gct cgg gtg gag aac tgc gcc gtc atc tac tgc aac gac ggc 324  
 Ala Asn Ala Arg Val Glu Asn Cys Ala Val Ile Tyr Cys Asn Asp Gly  
 35 40 45  
 50 ttc tgc gag ctg tgc ggc tac tgc cgg gcc gag gtg atg cag cga ccc 372  
 Phe Cys Glu Leu Cys Gly Tyr Ser Arg Ala Glu Val Met Gln Arg Pro  
 50 55 60  
 55 tgc acc tgc gac ttc ctg cac ggg ccg cgc acg cag cgc cgc gct gcc 420  
 Cys Thr Cys Asp Phe Leu His Gly Pro Arg Thr Gln Arg Arg Ala Ala  
 65 70 75  
 60 gcg cag atc gcg cag gca ctg ctg ggc gcc gag gag cgc aaa gtg gaa 468  
 Ala Gln Ile Ala Gln Ala Leu Leu Gly Ala Glu Glu Arg Lys Val Glu  
 80 85 90 95

-23-

	atc gcc ttc tac cgg aaa gat ggg agc tgc ttc cta tgt ctg gtg gat	516
	Ile Ala Phe Tyr Arg Lys Asp Gly Ser Cys Phe Leu Cys Leu Val Asp	
	100 105 110	
5	gtg gtg ccc gtg aag aac gag gat ggg gct gtc atc atg ttc atc ctc	564
	Val Val Pro Val Lys Asn Glu Asp Gly Ala Val Ile Met Phe Ile Leu	
	115 120 125	
10	aat ttc gag gtg gtg atg gag aag gac atg gtg ggg tcc ccg gct cat	612
	Asn Phe Glu Val Val Met Glu Lys Asp Met Val Gly Ser Pro Ala His	
	130 135 140	
15	gac acc aac cac cgg ggc ccc ccc acc agc tgg ctg gcc cca ggc cgc	660
	Asp Thr Asn His Arg Gly Pro Pro Thr Ser Trp Leu Ala Pro Gly Arg	
	145 150 155	
20	gcc aag acc ttc cgc ctg aag ctg ccc gcg ctg ctg gcg ctg acg gcc	708
	Ala Lys Thr Phe Arg Leu Lys Leu Pro Ala Leu Leu Ala Leu Thr Ala	
	160 165 170 175	
25	cgg gag tcg tcg gtg cgg tcg ggc ggc gcg ggc ggc gcg ggc gcc ccg	756
	Arg Glu Ser Ser Val Arg Ser Gly Gly Ala Gly Gly Ala Gly Ala Pro	
	180 185 190	
30	ggg gcc gtg gtg gtg gac gtg gac ctg acg ccc gcg gca ccc agc agc	804
	Gly Ala Val Val Val Asp Val Asp Leu Thr Pro Ala Ala Pro Ser Ser	
	195 200 205	
35	gag tcg ctg gcc ctg gac gaa gtg aca gcc atg gac aac cac gtg gca	852
	Glu Ser Leu Ala Leu Asp Glu Val Thr Ala Met Asp Asn His Val Ala	
	210 215 220	
40	ggg ctc ggg ccc gcg gag gag cgg cgt gcg ctg gtg ggt ccc ggc tct	900
	Gly Leu Gly Pro Ala Glu Glu Arg Arg Ala Leu Val Gly Pro Gly Ser	
	225 230 235	
45	ccg ccc cgc agc gcg ccc ggc cag ctc cca tcg ccc cgg gcg cac agc	948
	Pro Pro Arg Ser Ala Pro Gly Gln Leu Pro Ser Pro Arg Ala His Ser	
	240 245 250 255	
50	ctc aac ccc gac gcc tcg ggc tcc agc tgc agc ctg gcc cgg acg cgc	996
	Leu Asn Pro Asp Ala Ser Gly Ser Ser Cys Ser Leu Ala Arg Thr Arg	
	260 265 270	
55	tcc cga gaa agc tgc gcc agc gtg cgc cgc gcc tcg tcg gcc gac gac	1044
	Ser Arg Glu Ser Cys Ala Ser Val Arg Arg Ala Ser Ser Ala Asp Asp	
	275 280 285	
60	atc gag gcc atg cgc gcc ggg gtg ctg ccc ccg cca ccg cgc cac gcc	1092
	Ile Glu Ala Met Arg Ala Gly Val Leu Pro Pro Pro Pro Arg His Ala	
	290 295 300	
65	agc acc ggg gcc atg cac cca ctg cgc agc ggc ttg ctc aac tcc acc	1140
	Ser Thr Gly Ala Met His Pro Leu Arg Ser Gly Leu Leu Asn Ser Thr	
	305 310 315	
70	tcg gac tcc gac ctc gtg cgc tac cgc acc att agc aag att ccc caa	1188
	Ser Asp Ser Asp Leu Val Arg Tyr Arg Thr Ile Ser Lys Ile Pro Gln	
	320 325 330 335	
75	atc acc ctc aac ttt gtg gac ctc aag ggc gac ccc ttc ttg gct tcg	1236
	Ile Thr Leu Asn Phe Val Asp Leu Lys Gly Asp Pro Phe Leu Ala Ser	
	340 345 350	



5	ccc acc agt gac cgt gag atc ata gca cct aag ata aag gag cga acc 1284
	Pro Thr Ser Asp Arg Glu Ile Ile Ala Pro Lys Ile Lys Glu Arg Thr 355 360 365
10	cac aat gtc act gag aag gtc acc cag gtc ctg tcc ctg ggc gcc gac 1332
	His Asn Val Thr Glu Lys Val Thr Gln Val Leu Ser Leu Gly Ala Asp 370 375 380
15	gtg ctg cct gag tac aag ctg cag gca ccg cgc atc cac cgc tgg acc 1380
	Val Leu Pro Glu Tyr Lys Leu Gln Ala Pro Arg Ile His Arg Trp Thr 385 390 395
20	atc ctg cat tac agc ccc ttc aag gcc gtg tgg gac tgg ctc atc ctg 1428
	Ile Leu His Tyr Ser Pro Phe Lys Ala Val Trp Asp Trp Leu Ile Leu 400 405 410 415
25	ctg ctg gtc atc tac acg gct gtc ttc aca ccc tac tcg gct gcc ttc 1476
	Leu Leu Val Ile Thr Ala Val Phe Thr Pro Tyr Ser Ala Ala Phe 420 425 430
30	ctg ctg aag gag acg gaa gaa ggc ccg cct gct acc gag tgt ggc tac 1524
	Leu Leu Lys Glu Thr Glu Glu Gly Pro Pro Ala Thr Glu Cys Gly Tyr 435 440 445
35	gcc tgc cag ccg ctg gct gtg gtg gac ctc atc gtg gac atc atg ttc 1572
	Ala Cys Gln Pro Leu Ala Val Val Asp Leu Ile Val Asp Ile Met Phe 450 455 460
40	att gtg gac atc ctc atc aac ttc cgc acc acc tac gtc aat gcc aac 1620
	Ile Val Asp Ile Leu Ile Asn Phe Arg Thr Thr Tyr Val Asn Ala Asn 465 470 475
45	gag gag gtg gtc agc cac ccc ggc cgc atc gcc gtc cac tac ttc aag 1668
	Glu Glu Val Val Ser His Pro Gly Arg Ile Ala Val His Tyr Phe Lys 480 485 490 495
50	ggc tgg ttc ctc atc gac atg gtg gcc gcc atc ccc ttc gac ctg ctc 1716
	Gly Trp Phe Leu Ile Asp Met Val Ala Ala Ile Pro Phe Asp Leu Leu 500 505 510
55	atc ttc ggc tct ggc tct gag gag ctg atc ggg ctg ctg aag act gcg 1764
	Ile Phe Gly Ser Gly Ser Glu Glu Leu Ile Gly Leu Leu Lys Thr Ala 515 520 525
60	cgg ctg ctg cgg ctg gtg cgc gtg gcg cgg aag ctg gat cgc tac tca 1812
	Arg Leu Leu Arg Leu Val Arg Val Ala Arg Lys Leu Asp Arg Tyr Ser 530 535 540
65	gag tac ggc gcg gcc gtg ctg ttc ttg ctc atg tgc acc ttt gcg ctc 1860
	Glu Tyr Gly Ala Ala Val Leu Phe Leu Leu Met Cys Thr Phe Ala Leu 545 550 555
70	atc gcg cac tgg cta gcc tgc atc tgg tac gcc atc ggc aac atg gag 1908
	Ile Ala His Trp Leu Ala Cys Ile Trp Tyr Ala Ile Gly Asn Met Glu 560 565 570 575
75	cag cca cac atg gac tca cgc atc ggc tgg ctg cac aac ctg ggc gac 1956
	Gln Pro His Met Asp Ser Arg Ile Gly Trp Leu His Asn Leu Gly Asp 580 585 590
80	cag ata ggc aaa ccc tac aac agc agc ggc ctg ggc ggc ccc tcc atc 2004
	Gln Ile Gly Lys Pro Tyr Asn Ser Ser Gly Leu Gly Gly Pro Ser Ile

	595	600	605	
5	aag gac aag tat gtg acg gcg ctc tac ttc acc ttc agc agc ctc acc Lys Asp Lys Tyr Val Thr Ala Leu Tyr Phe Thr Phe Ser Ser Leu Thr 610 615 620			2052
10	agt gtg ggc ttc ggc aac gtc tct ccc aac acc aac tca gag aag atc Ser Val Gly Phe Gly Asn Val Ser Pro Asn Thr Asn Ser Glu Lys Ile 625 630 635			2100
15	ttc tcc atc tgc gtc atg ctc att ggc tcc ctc atg tat gct agc atc Phe Ser Ile Cys Val Met Leu Ile Gly Ser Leu Met Tyr Ala Ser Ile 640 645 650 655			2148
20	ttc ggc aac gtg tcg gcc atc atc cag cgg ctg tac tcg ggc aca gcc Phe Gly Asn Val Ser Ala Ile Ile Gln Arg Leu Tyr Ser Gly Thr Ala 660 665 670			2196
25	cgc tac cac aca cag atg ctg cgg gtg cgg gag ttc atc cgc ttc cac Arg Tyr His Thr Gln Met Leu Arg Val Arg Glu Phe Ile Arg Phe His 675 680 685			2244
30	cag atc ccc aat ccc ctg cgc cag cgc ctc gag gag tac ttc cag cac Gln Ile Pro Asn Pro Leu Arg Gln Arg Leu Glu Glu Tyr Phe Gln His 690 695 700			2292
35	gcc tgg tcc tac acc aac ggc atc gac atg aac gcg gtg ctg aag ggc Ala Trp Ser Tyr Thr Asn Gly Ile Asp Met Asn Ala Val Leu Lys Gly 705 710 715			2340
40	ttc cct gag tgc ctg cag gct gac atc tgc ctg cac ctg aac cgc tca Phe Pro Glu Cys Leu Gln Ala Asp Ile Cys Leu His Leu Asn Arg Ser 720 725 730 735			2388
45	ctg ctg cag cac tgc aaa ccc ttc cga ggg gcc acc aag ggc tgc ctt Leu Leu Gln His Cys Lys Pro Phe Arg Gly Ala Thr Lys Gly Cys Leu 740 745 750			2436
50	cgg gcc ctg gcc atg aag ttc aag acc aca cat gca ccg cca ggg gac Arg Ala Leu Ala Met Lys Phe Lys Thr Thr His Ala Pro Pro Gly Asp 755 760 765			2484
55	aca ctg gtg cat gct ggg gac ctg ctc acc gcc ctg tac ttc atc tcc Thr Leu Val His Ala Gly Asp Leu Leu Thr Ala Leu Tyr Phe Ile Ser 770 775 780			2532
60	cgg ggc tcc atc gag atc ctg cgg ggc gac gtc gtc gtg gcc atc ctg Arg Gly Ser Ile Glu Ile Leu Arg Gly Asp Val Val Val Ala Ile Leu 785 790 795			2580
65	ggg aag aat gac atc ttt ggg gag cct ctg aac ctg tat gca agg cct Gly Lys Asn Asp Ile Phe Gly Glu Pro Leu Asn Leu Tyr Ala Arg Pro 800 805 810 815			2628
70	ggc aag tcg aac ggg gat gtg cgg gcc ctc acc tac tgt gac cta cac Gly Lys Ser Asn Gly Asp Val Arg Ala Leu Thr Tyr Cys Asp Leu His 820 825 830			2676
75	aag atc cat cgg gac gac ctg ctg gag gtg ctg gac atg tac cct gag Lys Ile His Arg Asp Asp Leu Leu Glu Val Leu Asp Met Tyr Pro Glu 835 840 845			2724
80	ttc tcc gac cac ttc tgg tcc agc ctg gag atc acc ttc aac ctg cga			2772

	Phe	Ser	Asp	His	Phe	Trp	Ser	Ser	Leu	Glu	Ile	Thr	Phe	Asn	Leu	Arg	
			850					855						860			
5	gat	acc	aac	atg	atc	ccg	ggc	tcc	ccc	ggc	agt	acg	gag	tta	gag	ggt	2820
	Asp	Thr	Asn	Met	Ile	Pro	Gly	Ser	Pro	Gly	Ser	Thr	Glu	Leu	Glu	Gly	
		865					870				875						
10	ggc	ttc	agt	cgg	caa	cgc	aag	cgc	aag	ttg	tcc	ttc	cgc	agg	cgc	acg	2868
	Gly	Phe	Ser	Arg	Gln	Arg	Lys	Arg	Lys	Leu	Ser	Phe	Arg	Arg	Arg	Thr	
	880					885				890						895	
15	gac	aag	gac	acg	gag	cag	cca	ggg	gag	gtg	tgc	gcc	ttg	ggg	ccg	ggc	2916
	Asp	Lys	Asp	Thr	Glu	Gln	Pro	Gly	Glu	Val	Ser	Ala	Leu	Gly	Pro	Gly	
					900					905					910		
20	cgg	gcg	ggg	gca	ggg	ccg	agt	agc	cgg	ggc	cgg	ccg	ggg	ggg	ccg	tgg	2964
	Arg	Ala	Gly	Ala	Gly	Pro	Ser	Ser	Arg	Gly	Arg	Pro	Gly	Gly	Pro	Trp	
				915					920					925			
25	ggg	gag	agc	ccg	tcc	agt	ggc	ccc	tcc	agc	cct	gag	agc	agt	gag	gat	3012
	Gly	Glu	Ser	Pro	Ser	Ser	Gly	Pro	Ser	Ser	Pro	Glu	Ser	Ser	Glu	Asp	
			930					935					940				
30	gag	ggc	cca	ggc	cgc	agc	tcc	agc	ccc	ctc	cgc	ctg	gtg	ccc	ttc	tcc	3060
	Glu	Gly	Pro	Gly	Arg	Ser	Ser	Pro	Leu	Arg		Leu	Val	Pro	Phe	Ser	
		945					950					955					
35	agc	ccc	agg	ccc	ccc	gga	gag	ccg	ccg	ggg	ggg	gag	ccc	ctg	atg	gag	3108
	Ser	Pro	Arg	Pro	Pro	Gly	Glu	Pro	Pro	Gly	Gly	Glu	Pro	Leu	Met	Glu	
	960					965				970					975		
40	gac	tgc	gag	aag	agc	agc	gac	act	tgc	aac	ccc	ctg	tca	ggc	gcc	ttc	3156
	Asp	Cys	Glu	Lys	Ser	Ser	Asp	Thr	Cys	Asn	Pro	Leu	Ser	Gly	Ala	Phe	
					980					985					990		
45	tca	gga	gtg	tcc	aac	att	ttc	agc	ttc	tgg	ggg	gac	agt	cgg	ggc	cgc	3204
	Ser	Gly	Val	Ser	Asn	Ile	Phe	Ser	Phe	Trp	Gly	Asp	Ser	Arg	Gly	Arg	
				995				1000					1005				
50	cag	tac	cag	gag	ctc	cct	cga	tgc	ccc	gcc	ccc	acc	ccc	agc	ctc	ctc	3252
	Gln	Tyr	Gln	Glu	Leu	Pro	Arg	Cys	Pro	Ala	Pro	Thr	Pro	Ser	Leu	Leu	
			1010				1015					1020					
55	aac	atc	ccc	ctc	tcc	agc	ccg	ggg	cgg	cgg	ccc	cgg	ggc	gac	gtg	gag	3300
	Asn	Ile	Pro	Leu	Ser	Ser	Pro	Gly	Arg	Arg	Pro	Arg	Gly	Asp	Val	Glu	
		1025				1030					1035						
60	agc	agg	ctg	gat	gcc	ctc	cag	cgc	cag	ctc	aac	agg	ctg	gag	acc	cgg	3348
	Ser	Arg	Leu	Asp	Ala	Leu	Gln	Arg	Gln	Leu	Asn	Arg	Leu	Glu	Thr	Arg	
	1040				1045					1050					1055		
65	ctg	agt	gca	gac	atg	gcc	act	gtc	ctg	cag	ctg	cta	cag	agg	cag	atg	3396
	Leu	Ser	Ala	Asp	Met	Ala	Thr	Val	Leu	Gln	Leu	Leu	Gln	Arg	Gln	Met	
					1060				1065					1070			
70	acg	ctg	gtc	ccg	ccc	gcc	tac	agt	gct	gtg	acc	acc	ccg	ggg	cct	ggc	3444
	Thr	Leu	Val	Pro	Pro	Ala	Tyr	Ser	Ala	Val	Thr	Thr	Pro	Gly	Pro	Gly	
				1075				1080					1085				
75	ccc	act	tcc	aca	tcc	ccg	ctg	ttg	ccc	gtc	agc	ccc	ctc	ccc	acc	ctc	3492
	Pro	Thr	Ser	Thr	Ser	Pro	Leu	Leu	Pro	Val	Ser	Pro	Leu	Pro	Thr	Leu	
			1090				1095						1100				

-27-

acc ttg gac tcg ctt tct cag gtt tcc cag ttc atg gcg tgt gag gag 3540  
 Thr Leu Asp Ser Leu Ser Gln Val Ser Gln Phe Met Ala Cys Glu Glu  
 1105 1110 1115

5 ctg ccc ccg ggg gcc cca gag ctt ccc caa gaa ggc ccc aca cga cgc 3588  
 Leu Pro Pro Gly Ala Pro Glu Leu Pro Gln Glu Gly Pro Thr Arg Arg  
 1120 1125 1130 1135

10 ctc tcc cta ccg ggc cag ctg ggg gcc ctc acc tcc cag ccc ctg cac 3636  
 Leu Ser Leu Pro Gly Gln Leu Gly Ala Leu Thr Ser Gln Pro Leu His  
 1140 1145 1150

15 aga cac ggc tcg gac ccg ggc agt tag tggggctgcc cagtgtggac 3683  
 Arg His Gly Ser Asp Pro Gly Ser  
 1155 1160

acgtggctca cccagggatc aaggcgctgc tgggccgctc cccttggagg ccctgctcag 3743

20 gaggccctga ccgtggaagg ggagaggaac tcgaaagcac agtcctcccc ccagcccttg 3803  
 ggaccatctt ctctgcagt ccctggggcc ccagtgcagag gggcaggggc agggccggca 3863  
 gtaggtgggg cctgtggtcc cccactgcc ctgagggcat tagctggtct aactgcccgg 3923

25 aggcacccgg ccctgggcct taggcacctc aaggactttt ctgctattta ctgctcttat 3983  
 tgtaaggat aataattaag gatcatatga ataattaatg aagatgctga tgactatgaa 4043  
 taataaataa ttatcctgag gagaaaa 4070

30

<210> 2  
 <211> 1159  
 <212> PRT  
 35 <213> Homo sapiens

<400> 2  
 Met Pro Val Arg Arg Gly His Val Ala Pro Gln Asn Thr Phe Leu Asp  
 1 5 10 15  
 40 Thr Ile Ile Arg Lys Phe Glu Gly Gln Ser Arg Lys Phe Ile Ile Ala  
 20 25 30  
 Asn Ala Arg Val Glu Asn Cys Ala Val Ile Tyr Cys Asn Asp Gly Phe  
 35 40 45  
 45 Cys Glu Leu Cys Gly Tyr Ser Arg Ala Glu Val Met Gln Arg Pro Cys  
 50 55 60  
 Thr Cys Asp Phe Leu His Gly Pro Arg Thr Gln Arg Arg Ala Ala Ala  
 65 70 75 80  
 Gln Ile Ala Gln Ala Leu Leu Gly Ala Glu Arg Lys Val Glu Ile  
 85 90 95  
 50 Ala Phe Tyr Arg Lys Asp Gly Ser Cys Phe Leu Cys Leu Val Asp Val  
 100 105 110  
 Val Pro Val Lys Asn Glu Asp Gly Ala Val Ile Met Phe Ile Leu Asn  
 115 120 125  
 55 Phe Glu Val Val Met Glu Lys Asp Met Val Gly Ser Pro Ala His Asp  
 130 135 140  
 Thr Asn His Arg Gly Pro Pro Thr Ser Trp Leu Ala Pro Gly Arg Ala  
 145 150 155 160  
 Lys Thr Phe Arg Leu Lys Leu Pro Ala Leu Leu Ala Leu Thr Ala Arg  
 165 170 175  
 60 Glu Ser Ser Val Arg Ser Gly Gly Ala Gly Gly Ala Gly Ala Pro Gly  
 180 185 190  
 Ala Val Val Val Asp Val Asp Leu Thr Pro Ala Ala Pro Ser Ser Glu  
 195 200 205

Ser Leu Ala Leu Asp Glu Val Thr Ala Met Asp Asn His Val Ala Gly  
 210 215 220  
 Leu Gly Pro Ala Glu Glu Arg Arg Ala Leu Val Gly Pro Gly Ser Pro  
 225 230 235 240  
 5 Pro Arg Ser Ala Pro Gly Gln Leu Pro Ser Pro Arg Ala His Ser Leu  
 245 250 255  
 Asn Pro Asp Ala Ser Gly Ser Ser Cys Ser Leu Ala Arg Thr Arg Ser  
 260 265 270  
 10 Arg Glu Ser Cys Ala Ser Val Arg Arg Ala Ser Ser Ala Asp Asp Ile  
 275 280 285  
 Glu Ala Met Arg Ala Gly Val Leu Pro Pro Pro Pro Arg His Ala Ser  
 290 295 300  
 Thr Gly Ala Met His Pro Leu Arg Ser Gly Leu Leu Asn Ser Thr Ser  
 305 310 315 320  
 15 Asp Ser Asp Leu Val Arg Tyr Arg Thr Ile Ser Lys Ile Pro Gln Ile  
 325 330 335  
 Thr Leu Asn Phe Val Asp Leu Lys Gly Asp Pro Phe Leu Ala Ser Pro  
 340 345 350  
 20 Thr Ser Asp Arg Glu Ile Ile Ala Pro Lys Ile Lys Glu Arg Thr His  
 355 360 365  
 Asn Val Thr Glu Lys Val Thr Gln Val Leu Ser Leu Gly Ala Asp Val  
 370 375 380  
 Leu Pro Glu Tyr Lys Leu Gln Ala Pro Arg Ile His Arg Trp Thr Ile  
 385 390 395 400  
 25 Leu His Tyr Ser Pro Phe Lys Ala Val Trp Asp Trp Leu Ile Leu Leu  
 405 410 415  
 Leu Val Ile Tyr Thr Ala Val Phe Thr Pro Tyr Ser Ala Ala Phe Leu  
 420 425 430  
 30 Leu Lys Glu Thr Glu Glu Gly Pro Pro Ala Thr Glu Cys Gly Tyr Ala  
 435 440 445  
 Cys Gln Pro Leu Ala Val Val Asp Leu Ile Val Asp Ile Met Phe Ile  
 450 455 460  
 Val Asp Ile Leu Ile Asn Phe Arg Thr Thr Tyr Val Asn Ala Asn Glu  
 465 470 475 480  
 35 Glu Val Val Ser His Pro Gly Arg Ile Ala Val His Tyr Phe Lys Gly  
 485 490 495  
 Trp Phe Leu Ile Asp Met Val Ala Ala Ile Pro Phe Asp Leu Leu Ile  
 500 505 510  
 40 Phe Gly Ser Gly Ser Glu Glu Leu Ile Gly Leu Leu Lys Thr Ala Arg  
 515 520 525  
 Leu Leu Arg Leu Val Arg Val Ala Arg Lys Leu Asp Arg Tyr Ser Glu  
 530 535 540  
 Tyr Gly Ala Ala Val Leu Phe Leu Leu Met Cys Thr Phe Ala Leu Ile  
 545 550 555 560  
 45 Ala His Trp Leu Ala Cys Ile Trp Tyr Ala Ile Gly Asn Met Glu Gln  
 565 570 575  
 Pro His Met Asp Ser Arg Ile Gly Trp Leu His Asn Leu Gly Asp Gln  
 580 585 590  
 50 Ile Gly Lys Pro Tyr Asn Ser Ser Gly Leu Gly Gly Pro Ser Ile Lys  
 595 600 605  
 Asp Lys Tyr Val Thr Ala Leu Tyr Phe Thr Phe Ser Ser Leu Thr Ser  
 610 615 620  
 Val Gly Phe Gly Asn Val Ser Pro Asn Thr Asn Ser Glu Lys Ile Phe  
 625 630 635 640  
 55 Ser Ile Cys Val Met Leu Ile Gly Ser Leu Met Tyr Ala Ser Ile Phe  
 645 650 655  
 Gly Asn Val Ser Ala Ile Ile Gln Arg Leu Tyr Ser Gly Thr Ala Arg  
 660 665 670  
 60 Tyr His Thr Gln Met Leu Arg Val Arg Glu Phe Ile Arg Phe His Gln  
 675 680 685  
 Ile Pro Asn Pro Leu Arg Gln Arg Leu Glu Glu Tyr Phe Gln His Ala  
 690 695 700  
 Trp Ser Tyr Thr Asn Gly Ile Asp Met Asn Ala Val Leu Lys Gly Phe

705                      710                      715                      720  
 Pro Glu Cys Leu Gln Ala Asp Ile Cys Leu His Leu Asn Arg Ser Leu  
                                  725                      730                      735  
 5    Leu Gln His Cys Lys Pro Phe Arg Gly Ala Thr Lys Gly Cys Leu Arg  
                                  740                      745                      750  
 Ala Leu Ala Met Lys Phe Lys Thr Thr His Ala Pro Pro Gly Asp Thr  
                                  755                      760                      765  
 Leu Val His Ala Gly Asp Leu Leu Thr Ala Leu Tyr Phe Ile Ser Arg  
                                  770                      775                      780  
 10   Gly Ser Ile Glu Ile Leu Arg Gly Asp Val Val Val Ala Ile Leu Gly  
                                  785                      790                      795                      800  
 Lys Asn Asp Ile Phe Gly Glu Pro Leu Asn Leu Tyr Ala Arg Pro Gly  
                                  805                      810  
 15   Lys Ser Asn Gly Asp Val Arg Ala Leu Thr Tyr Cys Asp Leu His Lys  
                                  820                      825                      830  
 Ile His Arg Asp Asp Leu Leu Glu Val Leu Asp Met Tyr Pro Glu Phe  
                                  835                      840                      845  
 Ser Asp His Phe Trp Ser Ser Leu Glu Ile Thr Phe Asn Leu Arg Asp  
                                  850                      855                      860  
 20   Thr Asn Met Ile Pro Gly Ser Pro Gly Ser Thr Glu Leu Glu Gly Gly  
                                  865                      870                      875                      880  
 Phe Ser Arg Gln Arg Lys Arg Lys Leu Ser Phe Arg Arg Arg Thr Asp  
                                  885                      890                      895  
 25   Lys Asp Thr Glu Gln Pro Gly Glu Val Ser Ala Leu Gly Pro Gly Arg  
                                  900                      905                      910  
 Ala Gly Ala Gly Pro Ser Ser Arg Gly Arg Pro Gly Gly Pro Trp Gly  
                                  915                      920                      925  
 Glu Ser Pro Ser Ser Gly Pro Ser Ser Pro Glu Ser Ser Glu Asp Glu  
                                  930                      935                      940  
 30   Gly Pro Gly Arg Ser Ser Ser Pro Leu Arg Leu Val Pro Phe Ser Ser  
                                  945                      950                      955                      960  
 Pro Arg Pro Pro Gly Glu Pro Pro Gly Gly Glu Pro Leu Met Glu Asp  
                                  965                      970                      975  
 35   Cys Glu Lys Ser Ser Asp Thr Cys Asn Pro Leu Ser Gly Ala Phe Ser  
                                  980                      985                      990  
 Gly Val Ser Asn Ile Phe Ser Phe Trp Gly Asp Ser Arg Gly Arg Gln  
                                  995                      1000                      1005  
 Tyr Gln Glu Leu Pro Arg Cys Pro Ala Pro Thr Pro Ser Leu Leu Asn  
                                  1010                      1015                      1020  
 40   Ile Pro Leu Ser Ser Pro Gly Arg Arg Pro Arg Gly Asp Val Glu Ser  
                                  1025                      1030                      1035                      1040  
 Arg Leu Asp Ala Leu Gln Arg Gln Leu Asn Arg Leu Glu Thr Arg Leu  
                                  1045                      1050                      1055  
 45   Ser Ala Asp Met Ala Thr Val Leu Gln Leu Leu Gln Arg Gln Met Thr  
                                  1060                      1065                      1070  
 Leu Val Pro Pro Ala Tyr Ser Ala Val Thr Thr Pro Gly Pro Gly Pro  
                                  1075                      1080                      1085  
 Thr Ser Thr Ser Pro Leu Leu Pro Val Ser Pro Leu Pro Thr Leu Thr  
                                  1090                      1095                      1100  
 50   Leu Asp Ser Leu Ser Gln Val Ser Gln Phe Met Ala Cys Glu Glu Leu  
                                  1105                      1110                      1115                      1120  
 Pro Pro Gly Ala Pro Glu Leu Pro Gln Glu Gly Pro Thr Arg Arg Leu  
                                  1125                      1130                      1135  
 Ser Leu Pro Gly Gln Leu Gly Ala Leu Thr Ser Gln Pro Leu His Arg  
                                  1140                      1145                      1150  
 55   His Gly Ser Asp Pro Gly Ser  
                                  1155


## CLAIMS:

1. An assay for screening test compounds the assay comprising:
  - a) incubating a source containing HERG or a fragment thereof with;
    - i) a reference compound,
    - 5 ii) the test compound; and
  - b) measuring the effect of the test compound on the amount of reference compound bound to HERG.
- 10 2. An assay for screening test compounds for their capability to induce cardiotoxicity in a subject, the assay comprising:
  - a) incubating a source containing HERG or a fragment thereof with;
    - i) a reference compound,
    - ii) the test compound; and
  - b) measuring the effect of the test compound on the amount of reference  
15 compound bound to HERG.
3. An assay for screening test compounds for their capability to induce cardiac arrhythmia in a subject, the assay comprising:
  - a) incubating a source containing HERG or a fragment thereof with;
    - 20 i) a reference compound,
    - ii) the test compound; and
  - b) measuring the effect of the test compound on the amount of reference compound bound to HERG.
- 25 4. An assay according to any one of claims 1 to 3 wherein the source containing HERG is selected from the group consisting of:
  - i) an isolated and purified protein which encodes HERG having an amino acid sequence that is at least 80% identical to that of SEQ ID NO:2 or a fragment thereof;

- ii) an isolated and purified protein which encodes HERG comprising the amino acid sequence of SEQ ID NO: 2 or a fragment thereof;
  - iii) cells expressing on the surface thereof the HERG polypeptide channel or a fragment thereof; or
  - iv) membrane preparations of cells expressing on the surface thereof the HERG polypeptide channel or a fragment thereof.
- 5
5. An assay according to any one of claims 1 to 3 wherein the source containing HERG are membrane preparations of cells expressing on the surface thereof the
- 10 HERG polypeptide channel consisting of SEQ ID NO:2.
6. An assay according to any one of claims 1 to 3 wherein the reference compound is capable to induce cardiotoxicity in a subject.
- 15 7. An assay according to any one of claims 1 to 3 wherein the reference compound is selected from the group consisting of astemizole, terfenadine, erythromycin, sparfloxacin, probucol, terodiline and sertindole.
8. An assay according to any one of claims 1 to 3 wherein the reference compound
- 20 is astemizole.
9. An assay according to any one of claims 1 to 3 wherein the reference compound is labeled.
- 25 10. An assay according to claim 9 wherein the reference compound is radiolabeled.
11. An assay according to claim 10 wherein the reference compound is [ $H^3$ ]-astemizole.
- 30 12. Radiolabeled astemizole of formula (III)




-32-




III

13. A process for preparing radiolabeled astemizole as claimed in claim 12 characterised by:

- 5 a) demethylation of astemizole of formula (I) using a suitable reagent such as 48% aqueous hydrobromic acid; and



- b) reacting the intermediate of formula (II) with  $[3H^3]$ -methyl iodide ( $CT_3I$ ) optionally in a reaction inert solvent and in the presence of a base.



III

14. A high-throughput assay for screening test compounds, the assay comprising:
- a) contacting membrane preparations of cells expressing on the surface thereof HERG polypeptide channels having an amino acid sequence that is at least 80% identical to that of SEQ ID NO:2 or fragments thereof, with a labeled reference compound for a time sufficient to allow binding of the reference compound with the HERG polypeptide channel;
  - b) contacting membrane preparations of cells expressing on the surface thereof HERG polypeptide channels having an amino acid sequence that is at least 80% identical to that of SEQ ID NO:2 or fragments thereof, with the labeled reference compound of step a) together with the test compound for a time sufficient to allow binding of the reference compound and of the test compound with the HERG polypeptide channel;
  - c) measuring the amount of labeled reference compound bound to the HERG channel in step a);
  - d) measuring the amount of labeled reference compound bound to the HERG channel in step b); and
  - e) compare the amount of labeled reference compound bound to the HERG channel measured in step a) with the amount of labeled reference compound bound to the HERG polypeptide channel measured in step b).
15. A high-throughput proximity detection assay for screening test compounds the assay comprising:
- i) HERG labeled with a first label capable of participating in a proximity detection assay;
  - ii) a reference compound labeled with a second label capable of participating in a proximity detection assay;
  - iii) contacting HERG of step i) and a reference compound of step ii) together with a test compound for a time sufficient to allow binding of the reference compound and of the test compound to HERG; and

- iv) detect an interaction between HERG of step i) and a reference compound of step ii) by means of proximity of the first label with the second label when HERG and the reference compound interact.

5 16. A kit comprising:

- a) a source containing HERG;
- b) a reference compound.

10 17. A kit according to claim 16 wherein the source containing HERG is being selected from;

- i) an isolated and purified protein which encodes HERG having an amino acid sequence that is at least 80% identical to that of SEQ ID NO:2 or a fragment thereof;
- 15 ii) an isolated and purified protein which encodes HERG comprising the amino acid sequence of SEQ ID NO:2 or a fragment thereof;
- iii) cells expressing on the surface thereof the HERG polypeptide channel or a fragment thereof; or
- iv) membrane preparations of cells expressing on the surface thereof the HERG polypeptide channel or a fragment thereof.

20

18. A kit according to claim 16 wherein the source containing HERG is an isolated and purified HERG polypeptide channel or a fragment thereof, bound to a solid support.

25 19. A kit according to claim 18 wherein the solid support is a fluorescer comprising solid support.

20. A kit according to claim 16 wherein the source containing HERG consists of membrane preparations of cells expressing on the surface thereof HERG

polypeptide channels encoded by the amino acid sequence consisting of SEQ ID NO:2.

21. A kit according to claim 20 wherein said cells are HEK293 cells.
- 5 22. A kit according to claim any one of claims 16 to 21 wherein the reference compound is selected from the group consisting of astemizole, terfenadine, erythromycin, sparfloxacin, probucol, terodiline and sertindole.
- 10 23. A kit according to any one of claims 16 to 21 wherein the reference compound is labeled.
24. A kit according to claim 23 wherein the reference compound is radiolabeled.
- 15 25. A kit according to claim 24 wherein the reference compound is [ $H^3$ ]-astemizole.
26. A kit according to claim 23 optionally comprising means to remove the excess of unbound labeled reference compound from the incubation mixture.
- 20 27. A kit according to claim 23 wherein the separating means consist of GF/B filtration.
28. Use of an isolated and purified protein which encodes HERG comprising the amino acid sequence of SEQ ID NO:2 or a fragment thereof in an assay
- 25 according to any one of claims 1 to 3.
29. Use of an isolated and purified polynucleotide which encodes HERG comprising the nucleic acid sequence of SEQ ID NO:1 or a fragment thereof in an assay according to any one of claims 1 to 3.

30. Use of cells expressing on the surface thereof the HERG polypeptide channel comprising the amino acid sequence of SEQ ID NO:2 or a fragments thereof in an assay according to any one of claims 1 to 3.
- 5 31. Use of membrane preparations of cells expressing on the surface thereof the HERG polypeptide channel comprising the amino acid sequence of SEQ ID NO:2 or a fragments thereof in an assay according to any one of claims 1 to 3.
- 10 32. Use of membrane preparations of cells expressing on the surface thereof HERG polypeptide channels encoded by the amino acid sequence consisting of SEQ ID NO:2 in an assay according to any one of claims 1 to 3.
33. Use of astemizole in an assay according to any one of claims 1 to 3.
- 15 34. Use of labeled astemizole in an assay according to any one of claims 1 to 3.
35. Use of radiolabeled astemizole in an assay according to any one of claims 1 to 3.
36. Use of [H<sup>3</sup>]-astemizole in an assay according to any one of claims 1 to 3.

-1/2-

Figure 1 A






Figure 1 B



-2/2-

Figure 2

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/07364

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/50 C07D401/12 C07M5/00 G01N33/68 G01N33/60

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, BIOSIS, PAJ, MEDLINE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CLAYCOMB WILLIAM C ET AL: "HL-1 cells: A cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 6, 17 March 1998 (1998-03-17), pages 2979-2984, XP002198161 March 17, 1998 ISSN: 0027-8424 page 2982, column 2, line 9 - line 28; table 1  ----- -/--	1-6,9,10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

2 December 2002

Date of mailing of the international search report

10/12/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Gunster, M



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/07364

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHADWICK CHRISTOPHER C ET AL: "Identification of a specific radioligand for the cardiac rapidly activating delayed rectifier potassium channel." CIRCULATION RESEARCH, vol. 72, no. 3, 1993, pages 707-714, XP008002938 ISSN: 0009-7330 cited in the application figure 8; table 2	1-6,9,10
X	NETZER RAINER ET AL: "Screening lead compounds for QT interval prolongation." DRUG DISCOVERY TODAY, vol. 6, no. 2, 2001, pages 78-84, XP002198162 ISSN: 1359-6446	1-6,9, 10,14
Y	page 81, column 2, line 40 -page 82, column 1, line 8	7,8,15
Y	TAGLIALATELA M ET AL: "Cardiac ion channels and antihistamines: Possible mechanisms of cardiotoxicity." CLINICAL AND EXPERIMENTAL ALLERGY, vol. 29, no. SUPPL. 3, July 1999 (1999-07), pages 182-189, XP002198163 ISSN: 0954-7894 page 188, column 1, line 11 - line 22	7,8
Y	WO 00 70079 A (ORTHO MCNEIL PHARM INC) 23 November 2000 (2000-11-23) the whole document	15
T	FINLAYSON KEITH ET AL: "' <sup>3</sup> H!Dofetilide binding to HERG transfected membranes: A potential high throughput preclinical screen." EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 430, no. 1, 2001, pages 147-148, XP002198164 ISSN: 0014-2999 the whole document	1-6,9, 10,14
A	YAP Y G ET AL: "Arrhythmogenic mechanisms of non-sedating antihistamines." CLINICAL AND EXPERIMENTAL ALLERGY, vol. 29, no. SUPPL. 3, July 1999 (1999-07), pages 174-181, XP002198165 ISSN: 0954-7894 table 2	7

-/-

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/07364

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BISCHOFF ULRIKE ET AL: "Effects of fluoroquinolones on HERG currents." EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 406, no. 3, 2000, pages 341-343, XP002198166 ISSN: 0014-2999 abstract	7
A	----- DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 1998 (1998-11) JONES STEPHEN E ET AL: "Inhibition of the rapid component of the delayed-rectifier K <sup>+</sup> current by therapeutic concentrations of the antispasmodic agent terodiline." Database accession no. PREV199900046837 XP002198167 abstract & BRITISH JOURNAL OF PHARMACOLOGY, vol. 125, no. 6, November 1998 (1998-11), pages 1138-1143, ISSN: 0007-1188	7
A	----- DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; August 1998 (1998-08) RAMPE DAVID ET AL: "The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG." Database accession no. PREV199800441548 XP002198168 abstract & JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 286, no. 2, August 1998 (1998-08), pages 788-793, ISSN: 0022-3565	7
A	----- DATABASE MEDLINE 'Online! January 2000 (2000-01) DRICI M D ET AL: "Cardiac K <sup>+</sup> channels and drug-acquired long QT syndrome." Database accession no. NLM10860023 XP002198169 abstract & THERAPIE. ENGLAND 2000 JAN-FEB, vol. 55, no. 1, January 2000 (2000-01), pages 185-193, ISSN: 0040-5957 -----	7

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/07364

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0070079	A	23-11-2000	AU	4838500 A	05-12-2000
			WO	0070079 A1	23-11-2000

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**